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Hepatotoxicity is one of the most frequent forms of systemic toxicity of drugs and a leading cause for drug withdrawal from the market. To improve the possibilities to predict hepatotoxicity, Tzutzuy Ramirez and colleagues from BASF in Ludwigshafen recently tested a metabolomics based *in vitro* system (Ramirez et al., 2017\[[@R20]\]). They exposed HepG2 cells to 35 test compounds and applied LC-MS/MS as well as GC-MS to quantify 89 metabolites in the culture medium supernatant and 194 intracellular metabolites. A main focus was to determine quality criteria, such as reproducibility and concentration dependency of the test system. The relative standard deviations of technical replicates were in the range of 5-10 %, while controls from different days were between 10 and 15 % (Ramirez et al., 2017\[[@R20]\]). This is an excellent reproducibility for an *in vitro* system. Moreover, convincing concentration-response relationships were obtained and metabolite patterns could be associated with specific mechanisms of toxicity, such as peroxisome proliferation and liver enzyme induction or inhibition (Ramirez et al., 2017\[[@R20]\]). Therefore, the HepG2 metabolomics technique represents a promising new candidate in the field of *in vitro* hepatotoxicity prediction. Limitations are that the HepG2 cells show major metabolic differences compared to human hepatocytes. Moreover, the present study did not yet include a systematic comparison of negative and positive controls at *in vivo*relevant concentrations, which remains a challenge for the future.

Currently, mechanisms of hepatotoxicity represent a major focus in toxicological research (Kyriakides et al., 2016\[[@R18]\]; Ghallab, 2015\[[@R7]\]; Ramachandran et al., 2015\[[@R19]\]; Chen et al., 2015\[[@R4]\]; Campos et al., 2014\[[@R3]\]; Hammad et al., 2014\[[@R14]\]; Hassan, 2016\[[@R15]\]; Stöber, 2015\[[@R23]\]). Despite progress in the field of stem cell research (Gómez-Lechón and Tolosa, 2016\[[@R12]\]; Godoy et al., 2016\[[@R11]\]; Cameron et al., 2015\[[@R2]\]) and studies with cell lines (Tolosa et al., 2015\[[@R25]\]; Hewitt et al., 2007\[[@R16]\]; Godoy et al., 2013\[[@R10]\]), primary hepatocytes still remain a gold standard (Reif et al., 2015\[[@R22]\]; Grinberg et al., 2014\[[@R13]\]; Stöber, 2015\[[@R23]\]; Ghallab, 2015\[[@R6]\]; Arbo et al., 2016\[[@R1]\]). Moreover PBPK modeling (Ghallab, 2015\[[@R8]\]; Reif et al., 2017\[[@R21]\]; Thiel et al., 2015\[[@R24]\]) and spatio-temporal models (Ghallab et al., 2016\[[@R9]\]; Vartak et al., 2016\[[@R26]\]; Jansen et al., 2017\[[@R17]\]; Friebel et al., 2015\[[@R5]\]) have supported our understanding of the mechanisms of liver toxicity. The next year will show whether the novel HepG2 metabolomics assay can be integrated into useful test batteries for a better prediction of human hepatotoxicity.
